Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is ...

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On August 19, 2025, Aldeyra Therapeutics announced that the FDA granted Fast Track ...

Treatment With 9-cis Beta-Carotene-Rich Powder in Patients With Retinitis Pigmentosa: A Randomized Crossover Trial Rotenstreich Y, Belkin M, Sadetzki S, et al. JAMA Ophthalmol. 2013;131:985-992.

Retinitis pigmentosa is an eye disease in which there is damage to the retina. Approximately 2 million individuals (about 1 in 4,000) worldwide are affected by the condition, which typically ...